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A B S T R A C T
Background: There is some controversy regarding the effect of CYP2C19 polymorphism on clinical
outcome in patients receiving dual antiplatelet therapy (DAPT). Peripheral endothelial dysfunction has
recently been reported to predict adverse cardiovascular events. We hypothesized that CYP2C19 loss-of-
function (LOF) allele carriers with peripheral endothelial dysfunction had worse prognosis. The aim of
this study was to evaluate an additive effect of peripheral endothelial dysfunction on clinical outcome
following percutaneous coronary intervention (PCI) in patients with a CYP2C19 variant.
Methods: We enrolled 434 patients on DAPT following PCI. CYP2C19 genotype was examined, and we
divided patients into two groups: carriers, who had at least one CYP2C19 LOF allele, and non-carriers.
Peripheral endothelial dysfunction was examined using reactive hyperemia-peripheral arterial
tonometry index (RHI), and we divided patients into low and high RHI. Thus, subjects were divided
into four groups, and clinical events were followed up.
Results: A total of 55 patients had a cardiovascular event. Kaplan–Meier analysis demonstrated a
signiﬁcantly higher probability of cardiovascular events in carriers with low RHI (log-rank test:
p = 0.007). Multivariate Cox proportional hazards analysis identiﬁed both CYP2C19 LOF allele possession
(hazard ratio (HR): 1.94; 95% conﬁdence interval (CI): 1.1–3.69; p = 0.045) and lowRHI (HR: 2.15; 95% CI:
1.22–3.78; p = 0.008) as independent and signiﬁcant predictors of future cardiovascular events.
Conclusions: CYP2C19 LOF allele carriers with peripheral endothelial dysfunction were signiﬁcantly
correlatedwith cardiovascular events. The additional evaluation of peripheral endothelial function along
with CYP2C19 polymorphism might improve risk stratiﬁcation after coronary stent implantation.
 2015 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.Introduction
Percutaneous coronary intervention (PCI) is performed in
patients with coronary heart disease to improve symptoms and* Corresponding author at: Department of Cardiovascular Medicine, Graduate
School of Medical Sciences, Kumamoto University, 1-1-1, Honjo, Chuo-ku,
Kumamoto City 860-8556, Japan. Tel.: +81 96 373 5175; fax: +81 96 362 3256.
E-mail address: shokimot@kumamoto-u.ac.jp (S. Hokimoto).
http://dx.doi.org/10.1016/j.jjcc.2015.03.010
0914-5087/ 2015 Published by Elsevier Ltd on behalf of Japanese College of Cardioloclinical prognosis. Coronary artery stents, particularly drug-
eluting stents, are used to prevent abrupt closure of the stented
artery, as well as to lower the need for repeat revascularization.
Dual antiplatelet therapy (DAPT) is currently recommended for
the prevention of adverse cardiovascular events in patients
following coronary stenting [1–3]. Clopidogrel is the mainstay
drug for DAPT; however, some patients do not achieve an
adequate antiplatelet effect, and atherothrombotic events in-
cluding stent thrombosis are not completely inhibited [4,5]. The
antiplatelet efﬁcacy of clopidogrel varies widely, and amonggy.
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P450 (CYP) polymorphism correlate with diminished antiplatelet
efﬁcacy of clopidogrel and a high risk for adverse cardiovascular
events following stent implantation [6–10]. The incidence of the
CYP2C19 loss-of-function (LOF) genotype is higher in the
Japanese population than in Caucasians [11], and we have
demonstrated the relationship between CYP2C19 genotype and
an increased risk of cardiovascular events in Japanese coronary
heart disease patients following coronary stent implantation
[6,12,13].
Reactive hyperemia-peripheral arterial tonometry (RH-PAT),
which is used to measure the digital hyperemic response, is a
noninvasive, automatic and less operator-dependent test that is
clinically used to evaluate endothelial function [14,15]. It is
reported that the RH-PAT index (RHI) predicted adverse
cardiovascular events in patients without known coronary artery
disease [16], and we have reported that the RHI was useful for
identifying patients who were at high risk of ischemic heart
disease [17,18].
We hypothesized that adding the evaluation of RHI as an
assessment of peripheral endothelial function to CYP2C19
polymorphism would provide prognostic and predictive informa-
tion of cardiovascular events in patients following coronary stent
implantation.
Methods
The study complied with the Declaration of Helsinki regarding
investigation in humans, was approved by our institutional review
committee, and was conducted in accordance with the guidelines
of an ethics committee. Written informed consent was obtained
from all patients.
Study population
This was a prospective single-center study and a total of
600 consecutive patients who underwent PCI from January 2009 to
November 2012 in our hospital were eligible. We excluded
patients who were admitted for acute coronary syndrome;
patients treated with thrombolytic agents, ticlopidine, sarpogre-
late or cilostazol; and patients with deep vein thrombosis, atrial
ﬁbrillation, collagen disease, liver or renal dysfunction, and
malignant diseases. Thus, a total of 434 patients were enrolled
in this study. All patients underwent cardiac catheterization and
PCI during hospitalization, and they received DAPT with mainte-
nance doses of 100 mg/day of aspirin and 75 mg/day of clopidogrel
after a loading dose of 300 mg of clopidogrel.
Smoking status was determined via an interview. Subjects were
classiﬁed as having hypertension if they were receiving drug
treatment for hypertension or if they had a systolic pressure of at
least 140 mmHg or a diastolic pressure of at least 90 mmHg.
Dyslipidemia was deﬁned as low-density lipoprotein 140 mg/dl,
high-density lipoprotein <40 mg/dl, or triglyceride 150 mg/dl;
and diabetes as a 2-h glucose tolerance test ﬁnding of at least
200 mg/dl or a fasting glucose level of 126 mg/dl, hemoglobin
A1c 6.5%, physician-diagnosed diabetes, and/or use of diabetic
medication. Patients who had an ankle-brachial index value of
<0.90 in either leg were categorized as having peripheral arterial
disease. Chronic kidney disease was deﬁned as estimated
glomerular ﬁltration rate <60 mL/min/1.73 m2. Acute coronary
syndrome was deﬁned as either an acute myocardial infarction
(ST-elevation myocardial infarction or non-ST-elevation myocar-
dial infarction) or unstable angina pectoris according to the
American College of Cardiology/American Heart Association
guidelines [2,3].CYP2C19 genotyping
Genomic DNA was extracted from whole blood using the DNA
Extractor WB kit (Wako Pure Chemical Industries, Ltd., Osaka,
Japan) following the modiﬁed protocol described by Richards et al.
[19]. Polymerase chain reaction restriction fragment length
polymorphism analysis for CYP2C19*2 (681G>A) and CYP2C19*3
(636G>A) was performed as described previously [20,21].
CYP2C19*2 and *3 are considered to account for >99% of alleles
generating the null-activity enzyme in the Japanese population
[20]. Therefore, the subjects were divided according to the
CYP2C19 genotype into two groups: carriers: intermediate
metabolizers (IM; *1/*2, *1/*3) and poor metabolizers (PM; *2/*2,
*2/*3, *3/*3) carrying at least one CYP2C19 LOF allele, and non-
carriers: extensive metabolizers (EM; CYP2C19*1/*1) not carrying a
CYP2C19 LOF allele. In this study, we deﬁned carriers as those who
had at least one LOF allele and non-carriers as those who carried
homozygous normal-function alleles.
Assessment of endothelial function by reactive hyperemia-peripheral
arterial tonometry
Peripheral endothelial function was assessed by RH-PAT using
the EndoPAT2000 system (ItamarMedical, Franklin, MA, USA). RH-
PAT measurement is largely operator-independent, and a comput-
erized algorithm with an online system automatically calculated
the RH-PAT index (RHI); thus, therewasminimal interoperator and
intraoperator variability. The RH-PAT studies were performed as
described previously [17]. We used a natural logarithmic
transformation of the RH-PAT value to calculate the RHI:
RHI = Ln{[RH-PAT ratio]1  [0.2266  Ln(baseline) 0.2]} [17,22].
Previous studies demonstrated that RH-PAT technology has excel-
lent reproducibility [23,24]. We used the median value of the RHI
(0.55) to divide patients into low- and high-RHI groups.
Follow-up
After coronary stent implantation, patients were followed
prospectively at outpatient clinics until October 2013 or until an
endpoint occurred. We performed follow-up angiography 6–9
months after the procedure. We continued DAPT until the time of
follow-up angiography in stable patients and until one year in
acute coronary syndrome patients. We interrupted clopidogrel
after that time, and partly continued DAPT in cases of PCI for left
main trunk or complex lesions without a high risk of bleeding
complications. Cardiovascular events were ascertained from a
review of medical records and conﬁrmed by direct contact with
the patients, their families, and physicians. The endpoint was
a composite of cardiovascular death, nonfatal myocardial
infarction, ischemic stroke, unstable angina pectoris, coronary
revascularization, and hospitalization due to heart failure.
Cardiovascular death was deﬁned as death due to myocardial
infarction, congestive heart failure, or documented sudden
cardiac death. We used the universal deﬁnition of myocardial
infarction in this study [25]. The diagnosis of ischemic stroke was
based on clinical and radiological evidence of stroke. Coronary
revascularization was deﬁned as emergent revascularization for
unexpected hospitalization. In our institution, we performed PCI
for coronary lesions with myocardial ischemia assessed by
modalities such as electrocardiogram with exercise test, myocar-
dial scintigraphy, or intraprocedural measurement of fractional
ﬂow reserve. We included ischemia-driven revascularization as
the composite endpoint, and excluded revascularization therapy
based only on angiographic data. For subjects who had more than
2 cardiovascular events, only the ﬁrst event was considered in the
analysis.
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The Shapiro–Wilk test was used to assess the normal
distribution of continuous data. Continuous variables with a
normal distribution are expressed as the mean  SD. Categorical
data are presented as numbers or percentages. Differences between
2 groupswere tested using Fisher’s exact test for categorical variables.
Differences in continuous variables were analyzed by the unpaired t
test or the Mann–Whitney U test, as appropriate. We used the
Kaplan–Meier method to estimate the cardiovascular event proba-
bilities at 1730 days, and we also used the log-rank test to compare
distributions of survival times among groups. Univariate analysis was
performed using clinical variables that are considered to be
associated with cardiovascular events (CYP2C19 LOF allele posses-
sion, low-RHI status, sex, age, body mass index, hypertension,
dyslipidemia, diabetes, chronic kidney disease, current smoking,
acute coronary syndrome, peripheral arterial disease, previous
myocardial infarction, and previous stroke). Factors with a p-value
<1.0 were subsequently entered into multivariate analysis. Cox
proportional hazard models were used to calculate hazard ratios
(HRs). The results of this analysis are expressed as HRs for comparison
of risk with 95% conﬁdence intervals (CIs). A p-value <0.05 was
considered to denote statistical signiﬁcance. Statistical analyses were
performedusing SPSS version 22 software (IBM Institute Inc., Chicago,
IL, USA).
Results
Table 1 shows the characteristics of the subjects among the four
groups at baseline: carriers with low RHI (n = 135), carriers with
high RHI (n = 150), non-carriers with low RHI (n = 82), and non-
carriers with high RHI (n = 67). There was no signiﬁcant difference
in clinical characteristics among the four groups. The procedural
characteristics of PCI among the four groups are shown in
Table 2. CYP2C19 LOF genotypes distribution of *1/*1, *1/*2, *1/
*3, *2/*2, *2/*3, and *3/*3 was 34.6%, 34.8%, 11.3%, 10.8%, 6.7%, and
0.9%, respectively. This distribution was consistent with Hardy
Weinberg Equilibrium (p = 0.79). The RHI of the subjects was
0.59  0.24 and the median RHI was 0.55.
The data of 434 patients were available for analyzing
cardiovascular events. The mean follow-up period was 926 daysTable 1
Clinical characteristics of four groups according to carrier and RHI status.
Carrier (n=285)
Low RHI (n=135) (%) High RHI (n=150) (%)
Male 95 (70.4) 103 (68.7)
Age (years) 69.110.4 69.910.3
BMI (kg/m2) 24.03.7 23.83.2
Diabetes 65 (48.1) 72 (48.0)
Hypertension 99 (73.3) 108 (72.0)
Dyslipidemia 98 (72.6) 105 (70.0)
Current smoking 33 (24.4) 23 (15.3)
CKD 48 (35.6) 57 (38.0)
Previous MI 25 (18.5) 19 (12.7)
EF (%) 57.411.6 59.68.4
Previous stroke 18 (13.3) 18 (12.0)
PAD 19 (14.1) 16 (10.7)
Right ABI 1.090.16 1.12 0.15
Left ABI 1.090.15 1.11 0.13
Statin 131 (97.0) 136 (90.7)
b-Blocker 99 (73.3) 119 (79.3)
ACE-I/ARB 105 (77.8) 98 (65.3)
PPI 95 (70.4) 111 (74.0)
RHI, reactive hyperemia-peripheral arterial tonometry index; BMI, body mass index; C
peripheral arterial disease; ABI, ankle-brachial index; ACE-I, angiotensin-converting eand the median follow-up period was 923 days. We followed
patients up to 1730 days in this study. A total of 55 patients
suffered a cardiovascular event (Table 3). Details of the cardiovas-
cular events are as follows: cardiovascular death (n = 4), nonfatal
myocardial infarction (n = 4), stroke (n = 6), unstable angina
(n = 11), and coronary revascularization (n = 30). The frequency
of cardiovascular events was signiﬁcantly higher in the carrier
subjects with low RHI (p = 0.004). Sub-acute, late, or very late stent
thromboses were not observed within our follow-up periods.
Kaplan–Meier analysis demonstrated a signiﬁcantly higher prob-
ability of cardiovascular events in the carrier subjects with low RHI
(log-rank test: p = 0.007) (Fig. 1).
The results of the univariate and multivariate Cox proportional
hazards analyses for cardiovascular events are summarized in
Table 4. Univariate Cox proportional hazards analysis identiﬁed
CYP2C19 LOF allele possession (HR: 1.96; 95% CI: 1.03–3.71;
p = 0.04), low RHI (HR: 2.08; 95% CI: 1.19–3.64; p = 0.011), high age
(HR: 1.78; 95% CI: 1.05–3.04; p = 0.034), bodymass index (HR: 0.9;
95% CI: 0.83–0.98; p = 0.012), and peripheral arterial disease (HR:
2.52; 95% CI 1.38–4.62; p = 0.003) as signiﬁcant predictors of
clinical outcome. Multivariate Cox proportional hazards analysis
identiﬁed both possession of CYP2C19 LOF allele (HR: 1.94; 95% CI:
1.1–3.69; p = 0.045) and low RHI (HR: 2.15; 95% CI: 1.22–3.78;
p = 0.008) as independent and signiﬁcant predictors of future
cardiovascular events.
Discussion
This is the ﬁrst report to demonstrate that peripheral
endothelial dysfunction has a signiﬁcant and additive effect on
clinical outcome following coronary stent implantation in patients
with a CYP2C19 LOF allele. The ﬁndings of the present study are as
follows: (1) There was no signiﬁcant difference in clinical
characteristics among four groups. (2) CYP2C19 LOF allele carrier
patients with peripheral endothelial dysfunction had worse
prognosis than other groups. (3) Both CYP2C19 LOF allele
possession and peripheral endothelial dysfunction are signiﬁcant
and independent predictors of major cardiovascular events.
Coronary artery stents are useful to revascularize stenotic or
occluded coronary arteries and to prevent repeat revascularization.
Despite optimal treatment after coronary intervention, patientsNon-carrier (n=149) p
Low RHI (n=82) (%) High RHI (n=67) (%)
58 (70.7) 49 (73.1) 0.928
68.410.2 67.710.3 0.476
24.53.5 24.02.9 0.55
40 (48.8) 31 (46.3) 0.992
63 (76.8) 49 (73.1) 0.886
63 (76.8) 53 (79.1) 0.467
17 (20.7) 9 (13.4) 0.142
28 (34.1) 17 (25.4) 0.341
13 (15.9) 7 (10.4) 0.375
58.211.3 60.59.0 0.137
13 (15.9) 6 (9.0) 0.637
13 (15.9) 7 (10.4) 0.607
1.090.16 1.120.14 0.213
1.080.17 1.110.15 0.406
78 (95.1) 63 (94.0) 0.148
68 (82.9) 54 (80.6) 0.348
62 (75.6) 44 (65.7) 0.068
54 (65.9) 44 (65.7) 0.489
KD, chronic kidney disease; MI, myocardial infarction; EF, ejection fraction; PAD,
nzyme inhibitor; ARB, angiotensin receptor blocker; PPI, proton-pump inhibitor.
Table 2
Characteristics of percutaneous coronary implantation of four groups according to carrier and RHI status.
Carrier (n=285) Non-carrier (n=149) p
Low RHI (n=135) High RHI (n=150) Low RHI (n=82) High RHI (n=67)
Single vessel lesions 53 (39.3%) 54 (36.0%) 38 (46.3%) 23 (34.3%) 0.386
LMT 13 (9.6%) 21 (14.0%) 8 (9.8%) 9 (13.4%) 0.612
Bifurcation 10 (7.5%) 17 (11.3%) 10 (12.3%) 4 (6.2%) 0.426
DES only 88 (65.2%) 113 (75.3%) 52 (63.4%) 49 (73.1%) 0.142
Number of stents 1.57 0.96 1.67 0.96 1.750.98 1.571.01 0.506
RHI, reactive hyperemia-peripheral arterial tonometry index; LMT, left main trunk; DES, drug-eluting stent.
Table 3
Cardiovascular events encountered in low or high RHI between carrier and non-carrier groups.
Carrier (n=285) Non-carrier (n=149) p
Low RHI (n=135) High RHI (n=150) Low RHI (n=82) High RHI (n=67)
Total 28 (20.7%) 15 (10.0%) 9 (11.0%) 3 (4.5%) 0.004
Cardiovascular death 3 (2.2%) 0 (0%) 1 (1.2%) 0 (0%) 0.204
Myocardial infarction 2 (1.5%) 2 (1.3%) 0 (0%) 0 (0%) 0.546
Stroke 2 (1.5%) 3 (2.0%) 1 (1.2%) 0 (0%) 0.709
Unstable angina 7 (5.2%) 2 (1.3%) 1 (1.2%) 1 (1.5%) 0.134
Coronary revascularization 14 (10.4%) 8 (5.3%) 6 (7.3%) 2 (3.0%) 0.194
RHI, reactive hyperemia-peripheral arterial tonometry index.
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their risk is crucial. It has been reported that the possession of a
CYP2C19 LOF allele correlates with clinical outcome in patients
undergoing PCI and DAPT [26]. Although there is still some
controversy regarding this [27], we had clariﬁed that possession of
CYP2C19 LOF is associated with adverse clinical events in Japanese
patients [6,12], and that some clinical risk factors such as diabetes
and chronic kidney diseasemightmodify the effect of CYP2C19 LOF
on clinical outcome [28,29]. However, there are limited reports
regarding the effect of peripheral endothelial dysfunction on
carrier or non-carrier patients.
[(Fig._1)TD$FIG]
Fig. 1. Kaplan–Meier curves for primary composite endpoints during the follow-up
period among four groups: carriers with low RHI (n = 135), non-carriers with low
RHI (n = 82), carriers with high RHI (n = 150), and non-carriers with high RHI
(n = 67). CYP2C19 LOF allele carriers with low RHI had a worse prognosis than the
other groups (log-rank test: p = 0.007). RHI, reactive hyperemia-peripheral arterial
tonometry index; CYP, cytochrome P450.It has been reported that peripheral endothelial dysfunction
assessed by RH-PAT correlates with adverse cardiovascular events
in patients without known coronary artery disease or in high-risk
patients [16–18], but the impact of peripheral endothelial
dysfunction on clinical outcome in patients following coronary
stents has not yet been examined. Against this background, we
hypothesized that peripheral endothelial dysfunction has some
effect on clinical outcome in carrier or non-carrier patients after
coronary stent implantation, and our study demonstrated that
carrier status with low RHI is a signiﬁcant and independent
determinant of adverse cardiovascular events. The critical issue is
that CYP2C19 LOF allele carriers with low RHI hadworse prognosis
than other subjects. This suggests that more careful management
of cardiovascular risk factors is indicated in patients with both
CYP2C19 LOF and peripheral endothelial dysfunction.
Because there are limited reports on this issue, it is unclear why
peripheral endothelial dysfunction has a signiﬁcant effect on
patients with a CYP2C19 variant. Endothelial function plays
important roles in the maintenance of vascular tone, thrombosis,
platelet adhesion, and vasculature-blood cell homeostasis, and the
impaired endothelial function reﬂects early atherosclerotic
changes [30–32]. Atherosclerotic changes cause chronic inﬂam-
mation and include recruitment of platelets to the sites of
endothelial injury, leading to activation of platelet activity, and
it was recently reported that endothelial dysfunction is indepen-
dently associated with high platelet reactivity [33]. Thus, it is
possible that endothelial dysfunction has an additive effect on
higher platelet reactivity, leading to more cardiovascular events in
carriers. Endothelial function could be improved by appropriate
medications and lifestyle interventions [34,35], and treatment of
coronary risk factors by optimal medications could lead to
improvement of endothelial dysfunction, attenuate enhanced
platelet aggregation, and reduce cardiovascular events.
In the present study, we interrupted clopidogrel at the time of
follow-up angiography in stable patients and after one year in
acute coronary syndrome patients, so cardiovascular events might
not appear to be associatedwith the effect of CYP2C19 genotype on
clopidogrelmetabolism. In addition, a previous study reported that
the levels of platelet reactivity according to the CYP2C19 genotype
Table 4
Cox proportional hazards analysis for future cardiovascular events in patients following coronary stent implantation.
Variable Univariate regression Multivariate regression
HR 95% CI p-value HR 95% CI p-value
CYP2C19 LOF allele 1.96 1.03–3.71 0.04 1.94 1.1–3.69 0.045
Low RHI 2.08 1.19–3.64 0.011 2.15 1.22–3.78 0.008
Male 0.69 0.4–1.18 0.18
Age (>71 years) 1.78 1.05–3.04 0.034 1.55 0.89–2.71 0.12
BMI 0.9 0.83–0.98 0.012 0.93 0.86–1.01 0.1
Hypertension 1.38 0.73–2.62 0.32
Dyslipidemia 0.84 0.48–1.49 0.56
Diabetes 1.3 0.77–2.2 0.33
CKD 1.22 0.71–2.09 0.47
Current smoking 0.53 0.23–1.23 0.14
ACS 1.43 0.85–2.42 0.18
PAD 2.52 1.38–4.62 0.003 2.02 1.07–3.8 0.03
Previous MI 1.35 0.7–2.62 0.37
Previous stroke 1.2 0.57–2.55 0.63
HR, hazard ratio; CI, conﬁdence interval; LOF, loss-of-function; RHI, reactive hyperemia-peripheral arterial tonometry index; BMI, bodymass index; CKD, chronic kidney
disease; ACS, acute coronary syndrome; PAD, peripheral arterial disease; MI, myocardial infarction.
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a possibility that the risk of adverse clinical events after stent
implantation may be associated with CYP2C19 genotype itself, but
detailed mechanisms remain unclear.
It might seem strange that therewas no signiﬁcant difference in
the number of previous myocardial infarctions, previous strokes,
and peripheral arterial disease between low- and high-RHI groups
at baseline because peripheral endothelial dysfunction may play
an important role in progression of atherosclerotic diseases. An
impaired endothelial function is an early and fundamental event in
the development of atherosclerosis [37], so assessment of
endothelial function by RH-PAT might be more useful for the
patients without atherosclerotic co-morbidities. In the present
study, our subjects were patients with advanced atherosclerotic
diseases requiring PCI. Thus, low or high RHI might not make a
signiﬁcant difference in the number of previous myocardial
infarctions, previous strokes, or peripheral arterial disease. Further
study is needed to clarify our ﬁndings.
Conclusions
CYP2C19 LOF allele carriers with endothelial dysfunction were
signiﬁcantly correlated with adverse cardiovascular events. The
additional evaluation of peripheral endothelial function alongwith
CYP2C19 polymorphism might improve risk stratiﬁcation after
coronary stent implantation.
Study limitations
One limitation of this study is that it was performed in a single
center. Compared with previous Western studies, the number of
patients was small, and the studymay have been underpowered to
detect a difference in the clinical event rate. Therefore, a large
multiracial and multicenter study is required to conﬁrm our
results. In the present study, the endpoint was a composite
including unstable angina and revascularization. These might
appear to inﬂate the composite of events in patients with carrier
and low RHI. Moreover, we did notmeasure plasma concentrations
of the active metabolite of clopidogrel; thus, we cannot provide
direct evidence of the reduced antiplatelet efﬁcacy of clopidogrel in
patients with at least one CYP2C19 LOF allele. In addition, we
cannot exclude the effect of other drug metabolism enzymes, such
as CYP1A2, 2B6, 3A, and 2C9, on clopidogrel response, in addition
to CYP2C19. Further continuous clinical studies are necessary.Funding sources
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